The transaction is expected to be completed this month, but the company would not disclose the names of the bidders, he said. Ratiopharm is privately held and much about it is not publicly known. "It's clearly the crown jewel in the German generics market. For any interested party, for Europe, it's a megadeal," said David M Steinberg, an analyst with Deutsche Bank. "How profitable is it? 
Share:  <span class="sent">The transaction is expected to be completed this month, but the company would not disclose the names of the bidders, he said. <span class="company">Ratiopharm</span> is privately held and much about it is not publicly known.</span> "It's clearly the crown jewel in the German generics market. For any interested party, for Europe, it's a megadeal," said David M Steinberg, an analyst with Deutsche Bank. "How profitable is it? Tweet this 

The transaction is expected to be completed this month, but the company would not disclose the names of the bidders, he said. But Ratiopharm is privately held and much about it is not publicly known."It's clearly the crown jewel in the German generics market. For any interested party, for Europe, it's a megadeal," said David M. Steinberg, an analyst with Deutsche Bank . "How profitable is it? 
Share:  <span class="sent">The transaction is expected to be completed this month, but the company would not disclose the names of the bidders, he said. But <span class="company">Ratiopharm</span> is privately held and much about it is not publicly known."It's</span> clearly the crown jewel in the German generics market. For any interested party, for Europe, it's a megadeal," said David M. Steinberg, an analyst with Deutsche Bank . "How profitable is it? Tweet this 

He raised his 12 month price target to $30 from $27 Teva Pharmaceutical Industries Ltd: Deutsche Bank analyst David Steinberg reiterated his buy rating on shares of Teva Pharmaceutical Industries Ltd on Feb 16 Teva, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment 
Share:  He raised his 12 month price target to $30 from $27<span class="sent"> <span class="company">Teva</span> Pharmaceutical Industries Ltd: Deutsche Bank analyst <span class="analyst">David Steinberg</span> reiterated his buy rating on shares of <span class="company">Teva</span> Pharmaceutical Industries Ltd on Feb 16</span> <span class="company">Teva</span>, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment...He raised his 12 month price target to $30 from $27<span class="sent"> <span class="company">Teva</span> Pharmaceutical Industries Ltd: Deutsche Bank analyst <span class="analyst">David Steinberg</span> reiterated his buy rating on shares of <span class="company">Teva</span> Pharmaceutical Industries Ltd on Feb 16</span> <span class="company">Teva</span>, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment Tweet this 

On Tuesday, the stock nearly tripled in value after MAP said Levadex met all of its primary goals in a late stage trial. In a note to clients, Deutsche Bank analyst David Steinberg upgraded shares of Mountain View, Calif. based MAP to "Buy" from "Hold." He said Levadex, an inhalable product, is on track for a commercial launch in late 2011. He said U.S sales could rise to more than $250 million per year. 
Share:  On Tuesday, the stock nearly tripled in value after <span class="company">MAP</span> said Levadex met all of its primary goals in a late stage trial. <span class="sent"> In a note to clients, Deutsche Bank analyst <span class="analyst">David Steinberg</span> upgraded shares of Mountain View, Calif. based <span class="company">MAP</span> to "Buy" from "Hold." </span> He said Levadex, an inhalable product, is on track for a commercial launch in late 2011. He said U.S sales could rise to more than $250 million per year. ...On Tuesday, the stock nearly tripled in value after <span class="company">MAP</span> said Levadex met all of its primary goals in a late stage trial. <span class="sent"> In a note to clients, Deutsche Bank analyst <span class="analyst">David Steinberg</span> upgraded shares of Mountain View, Calif. based <span class="company">MAP</span> to "Buy" from "Hold." </span> He said Levadex, an inhalable product, is on track for a commercial launch in late 2011. He said U.S sales could rise to more than $250 million per year. ...On Tuesday, the stock nearly tripled in value after <span class="company">MAP</span> said Levadex met all of its primary goals in a late stage trial. <span class="sent"> In a note to clients, Deutsche Bank analyst <span class="analyst">David Steinberg</span> upgraded shares of Mountain View, Calif. based <span class="company">MAP</span> to "Buy" from "Hold." </span> He said Levadex, an inhalable product, is on track for a commercial launch in late 2011. Tweet this 

In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said David M. Steinberg, an analyst at Deutsche Bank . In the absence of serious competition, Allergan had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. 
Share:  <span class="sent">In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said <span class="analyst">David M. Steinberg</span>, an analyst at Deutsche Bank . </span> In the absence of serious competition, <span class="company">Allergan</span> had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. Tweet this 

In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said David M. Steinberg, an analyst at Deutsche Bank . In the absence of serious competition, Allergan had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. 
Share:  <span class="sent">In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said <span class="analyst">David M. Steinberg</span>, an analyst at Deutsche Bank . </span> In the absence of serious competition, <span class="company">Allergan</span> had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. Tweet this 

In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said David M. Steinberg, an analyst at Deutsche Bank . In the absence of serious competition, Allergan had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. 
Share:  <span class="sent">In the United States, "it's essentially been - what - an 18 year monopoly for Botox?" said <span class="analyst">David M. Steinberg</span>, an analyst at Deutsche Bank . </span> In the absence of serious competition, <span class="company">Allergan</span> had been able to raise the drug's price annually. But Dysport, which in Europe has been priced lower than Botox, has the potential to capture up to 20 percent of the market in this country he said. "Many doctors have been clamoring for another option," Mr. Steinberg said. Injectable botulinum toxins are purified forms of the bacterial poison that causes botulism , a paralyzing disease that can be fatal. Tweet this